These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 22169820)
1. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820 [TBL] [Abstract][Full Text] [Related]
2. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of drug loaded glycyrrhetinic acid modified alginate nanoparticles on mice bearing orthotopic liver tumor. Zhang C; Wu Y; Liu T; Zhao Y; Wang X; Wang W; Yuan Z J Control Release; 2011 Nov; 152 Suppl 1():e111-3. PubMed ID: 22195787 [No Abstract] [Full Text] [Related]
4. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860 [TBL] [Abstract][Full Text] [Related]
6. Redox- and light-responsive alginate nanoparticles as effective drug carriers for combinational anticancer therapy. Zhang C; Shi G; Zhang J; Niu J; Huang P; Wang Z; Wang Y; Wang W; Li C; Kong D Nanoscale; 2017 Mar; 9(9):3304-3314. PubMed ID: 28225139 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor activity of doxorubicin-loaded alginic-acid-based nanoparticles. Cheng Y; Yu S; Wang J; Qian H; Wu W; Jiang X Macromol Biosci; 2012 Oct; 12(10):1326-35. PubMed ID: 22887841 [TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy. Huang W; Wang W; Wang P; Tian Q; Zhang C; Wang C; Yuan Z; Liu M; Wan H; Tang H Acta Biomater; 2010 Oct; 6(10):3927-35. PubMed ID: 20438873 [TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765 [TBL] [Abstract][Full Text] [Related]
10. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731 [TBL] [Abstract][Full Text] [Related]
11. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting. Tian Q; Wang X; Wang W; Zhang C; Liu Y; Yuan Z Int J Pharm; 2010 Nov; 400(1-2):153-7. PubMed ID: 20813176 [TBL] [Abstract][Full Text] [Related]
12. Alginate/CaCO3 hybrid nanoparticles for efficient codelivery of antitumor gene and drug. Zhao D; Liu CJ; Zhuo RX; Cheng SX Mol Pharm; 2012 Oct; 9(10):2887-93. PubMed ID: 22894610 [TBL] [Abstract][Full Text] [Related]
13. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid. Tian Q; Wang XH; Wang W; Zhang CN; Wang P; Yuan Z Nanomedicine; 2012 Aug; 8(6):870-9. PubMed ID: 22100756 [TBL] [Abstract][Full Text] [Related]
14. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model. Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558 [TBL] [Abstract][Full Text] [Related]
15. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid. Wang X; Gu X; Wang H; Yang J; Mao S Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965 [TBL] [Abstract][Full Text] [Related]
16. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma. Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125 [TBL] [Abstract][Full Text] [Related]
17. Formulation and cytotoxicity of doxorubicin loaded in self-assembled bio-polyelectrolyte microshells. Tao X; Chen H; Sun XJ; Chen JF; Roa WH Int J Pharm; 2007 May; 336(2):376-81. PubMed ID: 17223293 [TBL] [Abstract][Full Text] [Related]
18. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091 [TBL] [Abstract][Full Text] [Related]
19. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060 [TBL] [Abstract][Full Text] [Related]
20. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Zhang L; Yao J; Zhou J; Wang T; Zhang Q Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]